Get to know our clinical trials

Clinical trial of SY-1425 plus azacitidine compared to placebo plus azacitidine, in adult patients with newly diagnosed high-risk, RARA-positive myelodysplastic syndrome

THE MAIN OBJECTIVE OF THIS TRIAL IS TO TEST THE EFFICACY OF SY-1425 ADDED TO AZACITIDINE IN THE TREATMENT OF MDS.

Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY OF SY-1425 PLUS AZACITIDINE COMPARED TO PLACEBO PLUS AZACITIDINE IN ADULT PATIENTS NEWLY DIAGNOSED WITH HIGH-RISK, RARA-POSITIVE MYELODYSPLASTIC SYNDROME.
  • Code EudraCT: 2020-004528-40
  • Protocol number: SY-1425-301
  • Promoter: Syros Pharmaceuticals, Inc

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.